Sparsentan
Sparsentan is a dual angiotensin II AT1 receptor and endothelin A receptor antagonist developed for the treatment of IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). By simultaneously blocking both the renin-angiotensin and endothelin pathways contributing to glomerular hypertension, proteinuria, and progressive renal fibrosis, it provides complementary nephroprotective effects beyond what is achievable with either pathway blockade alone. It has demonstrated significant reductions in proteinuria in clinical trials.
Moleküler Ağırlık
592,8000 g/mol
LogP
5,00
TPSA
122,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
2D Yapı
Cite this structure
Embed this structure
SMILES
CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(-c2ccccc2S(=O)(=O)Nc2noc(C)c2C)c(COCC)c1
InChI
InChI=1S/C32H40N4O5S/c1-5-7-14-29-33-32(17-10-11-18-32)31(37)36(29)20-24-15-16-26(25(19-24)21-40-6-2)27-12-8-9-13-28(27)42(38,39)35-30-22(3)23(4)41-34-30/h8-9,12-13,15-16,19H,5-7,10-11,14,17-18,20-21H2,1-4H3,(H,34,35)
Molecular Formula
C32H40N4O5S
HBD / HBA
1 / 8
Döndürülebilir Bağlar
12
Ağır Atomlar
42
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
Sparsentan is a dual angiotensin II AT1 receptor and endothelin A receptor antagonist developed for the treatment of IgA nephropathy (IgAN) and focal segmental glomerulosclerosis (FSGS). By simultaneously blocking both the renin-angiotensin and endothelin pathways contributing to glomerular hypertension, proteinuria, and progressive renal fibrosis, it provides complementary nephroprotective effects beyond what is achievable with either pathway blockade alone. It has demonstrated significant reductions in proteinuria in clinical trials.
Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.
Yes, Sparsentan is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL539423. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 10257882. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sparsentan"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sparsentan/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sparsentan/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sparsentan/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sparsentan"></drugfyi-drug>